HNP 2006
Alternative Names: HNP-2006Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator Hana Pharm
- Class Contrast media; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers; Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in CNS-cancer(Diagnosis, In volunteers) in South Korea (IV)
- 11 Dec 2020 Hana Pharm plans to files an IND application with the regulatory body in South Korea for phase II trials (Hana Pharm website, December 2020)
- 11 Dec 2020 Hana Pharm announces intention to launch HNP 2006 for CNS cancer (Diagnosis) in second half of 2023 (Hana Pharm website, December 2020)